Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transfusional Iron Overload”

51 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 51 results

Large-scale testing (Phase 3)Study completedNCT00235391
What this trial is testing

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Who this might be right for
ThalassemiaSickle Cell DiseaseDiamond Blackfan Anemia+1 more
Novartis Pharmaceuticals 1,683
Large-scale testing (Phase 3)UnknownNCT01511848
What this trial is testing

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

Who this might be right for
Beta-thalassemia MajorSickle Cell DiseaseIron Hemosiderosis
Ain Shams University 60
Post-approval studies (Phase 4)Study completedNCT00673608
What this trial is testing

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Who this might be right for
HemoglobinopathiesMyelodysplastic SyndromesOther Inherited or Acquired Anaemia+4 more
Novartis 118
Post-approval studies (Phase 4)Ended earlyNCT01326845
What this trial is testing

Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study

Who this might be right for
Myelodysplastic SyndromeTransfusional Iron Overload
Novartis Pharmaceuticals 12
Testing effectiveness (Phase 2)Study completedNCT00940602
What this trial is testing

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 225
Testing effectiveness (Phase 2)Study completedNCT00069862
What this trial is testing

Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia

Who this might be right for
Beta-Thalassemia
Genzyme, a Sanofi Company 25
Large-scale testing (Phase 3)Study completedNCT00171210
What this trial is testing

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

Who this might be right for
Transfusional Iron Overload in β-thalassemia
Novartis Pharmaceuticals 506
Testing effectiveness (Phase 2)Study completedNCT00395629
What this trial is testing

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Who this might be right for
Iron OverloadHereditary Hemochromatosis
Novartis Pharmaceuticals 49
Testing effectiveness (Phase 2)Study completedNCT01709032
What this trial is testing

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

Who this might be right for
Thalassemia Major With Severe Transfusional Iron Overload
Children's Hospital of Philadelphia 9
Early research (Phase 1)Study completedNCT00560820
What this trial is testing

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

Who this might be right for
β-thalassemiaTransfusional Iron Overload
Novartis Pharmaceuticals 11
Post-approval studies (Phase 4)Study completedNCT01250951
What this trial is testing

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

Who this might be right for
Myelodysplastic SyndromeThalassemia
Novartis Pharmaceuticals 111
Testing effectiveness (Phase 2)Ended earlyNCT00602446
What this trial is testing

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Who this might be right for
Breast CancerIron OverloadLeukemia+5 more
Masonic Cancer Center, University of Minnesota 4
Testing effectiveness (Phase 2)Study completedNCT00379483
What this trial is testing

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

Who this might be right for
Transfusional Iron Overload
Novartis Pharmaceuticals 66
Early research (Phase 1)Study completedNCT01039636
What this trial is testing

Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload

Who this might be right for
Transfusional Iron OverloadBeta-thalassemia
FerroKin BioSciences, Inc. 20
Testing effectiveness (Phase 2)Ended earlyNCT01363908
What this trial is testing

Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload

Who this might be right for
Transfusional Iron OverloadBeta-Thalassemia
Shire 30
Testing effectiveness (Phase 2)Study completedNCT00000595
What this trial is testing

Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

Who this might be right for
Anemia (Iron-Loading)Beta-ThalassemiaHematologic Diseases+4 more
National Heart, Lung, and Blood Institute (NHLBI)
Not applicableStudy completedNCT01965171
What this trial is testing

Transfusional Iron Overload Among Leukemia Survivors

Who this might be right for
Acute Lymphocytic LeukemiaAcute Myeloid Leukemia
St. Jude Children's Research Hospital 24
Post-approval studies (Phase 4)Study completedNCT00117507
What this trial is testing

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Who this might be right for
Myelodysplastic SyndromesIron Overload
Novartis Pharmaceuticals 24
Large-scale testing (Phase 3)Study completedNCT00061750
What this trial is testing

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

Who this might be right for
Beta-Thalassemia
Novartis Pharmaceuticals 595
Not applicableStudy completedNCT04171635
What this trial is testing

Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

Who this might be right for
MRI Scans
Weill Medical College of Cornell University 55
Load More Results